| |
back to
media page
FRAXELฎ
LASER
RECEIVES
FDA
CLEARANCE
FOR
TREATMENT
OF MELASMA
On July
27,
Reliant
announced
that the
Fraxel
laser
received
FDA
clearance
to treat
melasma, a
stubborn
skin
condition
estimated
to affect
6 million
women
worldwide.
Until now,
melasma
has been
resistant
to
treatment,
with
traditional
laser and
pulsed-light
procedures
considered
unsatisfactory
due to
lackluSiter
results,
significant
downtime
or the
risk of
adverse
complications.
We are
delighted
to finally
have a
successful
laser
treatment
to offer
patients
who have
been
forced to
view the
world and
be viewed
by the
world
through a
mask that
could
never be
removed,
says
dermatologist
Cameron K.
Rokhsar,
MD, of New
York, NY,
who
authored a
landmark
paper on
the topic.
With the
Fraxel
lasers
unique
approach
of using
millions
of
microscopic
thermal
spots to
gently
resurface
only
portions
of skin at
a time, we
can now
penetrate
deep
enough to
eliminate
the
melanocytes
that cause
melasma.
We are
delighted
to finally
have a
successful
laser
treatment
to offer
patients
who have
been
forced to
view the
world and
be viewed
by the
world
through a
mask that
could
never be
removed.
Cameron
K.
Rokhsar,
MD
Dr.
Rokhsar's
study has
been
submitted
to the
American
Society of
Dermatologic
Surgeons
for
presentation
at their
annual
meeting in
October
and was
accepted
by
Dermatologic
Surgery
with a
expected
publication
date of
December.
He joined
world
renowned
laser
pioneer
Dr.
Richard
Fitzpatrick
in the
ground
breaking
study: By
employing
fractional
resurfacing
with its
distinctive
wound
healing
response,
we can not
only
resolve
the
excessive
and
undesirable
pigmentation
at the
dermal
junction,
but also
avoid
aggravating
the
surrounding
melanocytes,
preventing
inflammatory
post-treatment
responses,
explains
Dr.
Fitzpatrick.
|
|
